Protagonist Therapeutics, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
74366E102
SEDOL
BDCBCD8
CIK
0001377121
www.protagonist-inc.com
LEI:
©
FIGI: BBG002B63KM7
PTGX
Protagonist Therapeutics, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Protagonist Therapeutics, Inc.
ISIN
US74366E1029
TICKER
PTGX
MIC
XNAS
REUTERS
PTGX.OQ
BLOOMBERG
PTGX US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by AccessWire.

Thu, 21.11.2024       Protagonist Therapeutics
US74366E1029

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, ...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Protagonist Therapeutics
US74366E1029

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 ant...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Protagonist Therapeutics
US74366E1029

NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor in plaque psoriasisICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       Protagonist Therapeutics
US74366E1029

Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025Top line results for rusfertide Phase 3 VERIFY clinical trial in polycyth...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       Protagonist Therapeutics
US74366E1029

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in ...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.10.2024       Protagonist Therapeutics
US74366E1029

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 sh...
Read More
Protagonist Therapeutics
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements